This post was originally published on this site
The industry’s revenue increased 26.9% year-over-year and 6.7% sequentially in the second quarter of 2021. Moreover, the burgeoning genomics and healthcare technology segments are expected to revolutionize the industry in the near term.
So far, the industry has demonstrated immense growth potential, with significant progress in smart healthcare and innovative breakthroughs. Given the industry’s vitality and its growth prospects, we think that fundamentally sound healthcare stocks Global Cord Blood Corporation (CO) and IRIDEX Corporation (IRIX), which are currently trading more than 25% below their 52-week price highs, could be good bets now. These stocks are rated ‘Strong Buy’ in our proprietary POWR Ratings system.
